CRP and neoplasm: The study found an independent association between the occurrence of immune-related adverse events and improved overall survival in a real-world cohort across multiple tumor types and treatment regimens. Pre-treatment comorbidities, CRP and eosinophil count are potential markers for predicting treatment response.